Cargando…
Inhibitor of H3K27 demethylase JMJD3/UTX GSK-J4 is a potential therapeutic option for castration resistant prostate cancer
Androgen receptor (AR) mediates initiation and progression of prostate cancer (PCa); AR-driven transcription is activated by binding of androgens to the ligand-binding domain (LBD) of AR. Androgen ablation therapy offers only a temporary relief of locally advanced and metastatic PCa, and the disease...
Autores principales: | Morozov, Viacheslav M., Li, Ying, Clowers, Matthew M., Ishov, Alexander M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5617492/ https://www.ncbi.nlm.nih.gov/pubmed/28977932 http://dx.doi.org/10.18632/oncotarget.19100 |
Ejemplares similares
-
Histone H3 Lysine 27 demethylases Jmjd3 and Utx are required for T-cell differentiation
por: Manna, Sugata, et al.
Publicado: (2015) -
Histone demethylases UTX and JMJD3 are required for NKT cell development in mice
por: Northrup, Daniel, et al.
Publicado: (2017) -
The Memory of Environmental Chemical Exposure in C. elegans Is Dependent on the Jumonji Demethylases jmjd-2 and jmjd-3/utx-1
por: Camacho, Jessica, et al.
Publicado: (2018) -
Targeting Esophageal Squamous Cell Carcinoma by Combining Copper Ionophore Disulfiram and JMJD3/UTX Inhibitor GSK J4
por: Yang, Canlin, et al.
Publicado: (2023) -
The pharmacological role of histone demethylase JMJD3 inhibitor GSK-J4 on glioma cells
por: Sui, Aixia, et al.
Publicado: (2017)